THC Crossover Study

NACompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

October 30, 2020

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2024

Conditions
THCCannabisCannabis SmokingCannabis Use, UnspecifiedCigarette SmokingTobacco UseNicotine DependenceNicotine WithdrawalCardiovascular Risk Factor
Interventions
OTHER

Smoked Cannabis

Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff.

OTHER

Vaped Cannabis

Cannabis will be purchased by the participants and reimbursed the full cost by the study. Participants will be asked to purchase enough to last 2 full days of use. To reduce variability between products, participants will be asked to purchase cannabis from one dispensary near the research facility (Purple Star MD at 2520 Mission St., San Francisco). Receipt must be provided to study staff. All participants will use the study-provided PAX® (PAX 2) dry herb vaporizer, one of the most popular handheld vaporizers.

OTHER

Tobacco Cigarette

Tobacco cigarettes of participants' choice (usual brand) will be provided by research staff for use on the study.

Trial Locations (2)

94110

Zuckerberg San Francisco General Hospital, San Francisco

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Tobacco Related Disease Research Program

OTHER

lead

University of California, San Francisco

OTHER

NCT04429568 - THC Crossover Study | Biotech Hunter | Biotech Hunter